Abstract
The in vitro activities of CG400549, a novel FabI inhibitor, were compared to those of linezolid and commonly used antimicrobials against recent bacterial isolates. CG400549 had an MIC90 of 0.5 μg/ml for Staphylococcus aureus strains and was more potent than either linezolid or vancomycin.
Original language | English |
---|---|
Pages (from-to) | 2591-2593 |
Number of pages | 3 |
Journal | Antimicrobial agents and chemotherapy |
Volume | 51 |
Issue number | 7 |
DOIs | |
Publication status | Published - 2007 Jul |
All Science Journal Classification (ASJC) codes
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases